Genocea Biosciences Inc.

2.10-0.1100-4.98%Vol 405.10K1Y Perf 1.47%
Apr 19th, 2021 16:00 DELAYED
BID2.06 ASK2.15
Open2.24 Previous Close2.21
Pre-Market- After-Market2.13
 - -  0.03 1.43%
Target Price
6.35 
Analyst Rating
Strong Buy 1.00
Potential %
202.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
+     36.80
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Market Cap112.39M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
8.98 
Earnings Date
29th Apr 2021

Today's Price Range

2.022.25

52W Range

1.745.75

5 Year PE Ratio Range

-1.40-0.6000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.70%
1 Month
-29.53%
3 Months
-35.58%
6 Months
-14.98%
1 Year
1.47%
3 Years
-69.65%
5 Years
-94.93%
10 Years
-

TickerPriceChg.Chg.%
GNCA2.10-0.1100-4.98
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
3.20
3.30
0.48
2.66
-30.70
Leverage Ratio 8.40
ProfitabilityValueIndustryS&P 500US Markets
-
-2 714.70
-2 630.90
-
-
RevenueValueIndustryS&P 500US Markets
1.36M
0.02
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.21-0.1814.29
Q03 2020-0.24-0.26-8.33
Q02 2020-0.41-0.394.88
Q01 2020-0.37-0.46-24.32
Q04 2019-0.41-0.3417.07
Q03 2019-0.45-0.2837.78
Q02 2019-0.65-0.67-3.08
Q01 2019-0.72-0.720.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.2013.04Positive
6/2021 QR-0.2016.67Positive
12/2021 FY-0.813.57Positive
12/2022 FY-0.82-1.23Negative
Next Report Date29th Apr 2021
Estimated EPS Next Report-0.20
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume405.10K
Shares Outstanding53.52M
Trades Count1.38K
Dollar Volume1.32M
Avg. Volume552.87K
Avg. Weekly Volume366.69K
Avg. Monthly Volume382.96K
Avg. Quarterly Volume541.16K

Genocea Biosciences Inc. (NASDAQ: GNCA) stock closed at 2.1 per share at the end of the most recent trading day (a -4.98% change compared to the prior day closing price) with a volume of 406.20K shares and market capitalization of 112.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 72 people. Genocea Biosciences Inc. CEO is William D. Clark.

The one-year performance of Genocea Biosciences Inc. stock is 1.47%, while year-to-date (YTD) performance is -13.22%. GNCA stock has a five-year performance of -94.93%. Its 52-week range is between 1.74 and 5.75, which gives GNCA stock a 52-week price range ratio of 8.98%

Genocea Biosciences Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 13.17, a price-to-sale (PS) ratio of 84.01, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.13%, a ROC of -77.20% and a ROE of -246.39%. The company’s profit margin is -%, its EBITDA margin is -2 630.90%, and its revenue ttm is $1.36 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Genocea Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Genocea Biosciences Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Genocea Biosciences Inc. is Strong Buy (1), with a target price of $6.35, which is +202.38% compared to the current price. The earnings rating for Genocea Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genocea Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genocea Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.13, ATR14 : 0.29, CCI20 : -211.71, Chaikin Money Flow : -0.27, MACD : -0.23, Money Flow Index : 27.87, ROC : -22.51, RSI : 33.92, STOCH (14,3) : 9.41, STOCH RSI : 0.00, UO : 29.54, Williams %R : -90.59), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genocea Biosciences Inc. in the last 12-months were: Ali Behbahani (Buy at a value of $409 664), Anthony A. Florence (Buy at a value of $409 664), Carmen Chang (Buy at a value of $409 664), Forest Baskett (Buy at a value of $7 090 335), Joshua Makower (Buy at a value of $409 664), Peter Sonsini (Buy at a value of $409 664), Sandell D Scott (Buy at a value of $409 664), William D. Clark (Buy at a value of $9 806), William D. Clark (Option Excercise at a value of $81 785)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Genocea Biosciences Inc.

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

CEO: William D. Clark

Telephone: +1 617 876-8191

Address: 100 Acorn Park Drive, Cambridge 02140, MA, US

Number of employees: 72

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

47%53%

News

Stocktwits